An 87-year-old man was admitted complaining of cough after he had been treated with drugs at another hospital. Chest X-ray revealed multiple nodules, and chest computed tomography (CT) showed metastatic lung tumors. Abdominal CT revealed staining of the outer portion of the prostate by contrast medium, though this finding was considered nonspecific and nondiagnostic. A CT-guided biopsy of a lung tumor was performed, and the lung tumor was found to be positive for prostate-specific antigen (PSA). Prostate carcinoma was diagnosed by prostate biopsy, which yielded the same findings as the lung tumor. The serum PSA level was high. No metastases except for pulmonary lesions were observed on a bone scintigram and abdominal CT. Prostate carcinoma with pulmonary metastases alone was therefore diagnosed. The present case represents a rare case of pulmonary metastases without any other metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310052 | PMC |
| http://dx.doi.org/10.2185/jrm.2875 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
This case report is about an 84-year-old female patient with a history of high-grade serous ovarian carcinoma who was diagnosed with a renal pseudotumor. Initial imaging in February 2023 showed signs of a renal cell carcinoma and possible lung metastases. A CT-guided biopsy and histopathological analysis ruled out malignancy and confirmed a benign inflammatory pseudotumor.
View Article and Find Full Text PDFDiverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer.
Oncol Lett
March 2025
Division of Chest Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua 50006, Taiwan, ROC.
EGFR and ALK are key driver mutations in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors are recommended as the first-line treatment for advanced NSCLC with driving oncogenes because they have fewer side effects and provide better disease control than chemotherapy. The present retrospective analysis aimed to investigate how altered driver genes impact cancer outcomes and clinical presentation.
View Article and Find Full Text PDFEfficacy evaluation of prophylactic cranial irradiation for limited stage small‑cell lung cancer in the magnetic resonance imaging era: A meta‑analysis.
Oncol Lett
March 2025
Department of Radiotherapy, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou, Gansu 730050, P.R. China.
The role of prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (LS-SCLC) remains controversial in the era of magnetic resonance imaging (MRI). The present study aimed to evaluate the effectiveness of PCI in the treatment of LS-SCLC in the era of MRI. The PubMed, EMBASE and Cochrane Library databases were searched from the time of database creation until May 24, 2023, to identify clinical studies that evaluated the effectiveness of PCI in patients with LS-SCLC in the MRI era.
View Article and Find Full Text PDFHigh‑intensity focused ultrasound thermal ablation boosts the efficacy of immune checkpoint inhibitors in advanced cancers with liver metastases: A single‑center retrospective cohort study.
Oncol Lett
March 2025
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, P.R. China.
High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and is not affected by dose limits. This retrospective study aimed to explore the efficacy of HIFU in improving survival and the safety of the method in newly diagnosed patients with cancer with LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 and December 2023, data from 438 newly diagnosed patients with cancer and LIM who were treated at Mianyang Central Hospital (Mianyang, China) were reviewed.
View Article and Find Full Text PDFDevelopment and internal validation of prognostic models for event-free survival in newly diagnosed Ewing sarcoma patients based on routinely collected clinical characteristics from the European randomised controlled trial, EE2012.
BMJ Open
December 2024
Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
Introduction: Ewing sarcoma is a rare paediatric cancer. Currently, there is no way of accurately predicting these patients' survival at diagnosis. Disease type (ie, localised disease, lung/pleuropulmonary metastases and other metastases) is used to guide treatment decisions, with metastatic patients generally having worse outcomes than localised disease patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!